Remove 2028 Remove FDA Remove Safety
article thumbnail

#ASH22: Pirtobrutinib emerges as an option for Richter’s Transformation

Pharmaceutical Technology

Due to the rarity of the disease, no FDA-approved therapy exists specifically for RT, and these patients are treated using regimens derived from the DLBCL treatment paradigm and other small-scale clinical trials. In the pirtobrutinib safety cohort, only 2.6% of patients discontinued treatment due to adverse events.

FDA 59
article thumbnail

More big wins for the AstraZeneca-Daiichi Sankyo collaboration

Pharmaceutical Technology

Enhertu has already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma, with annual sales for these indications alone expected to exceed $1.3bn by 2028.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key developments: mRNA vaccines and therapeutics

European Pharmaceutical Review

Robust analytical methods are needed to establish safety, potency, and purity of mRNA therapeutics in large-scale manufacturing. Sarah Bundra, Pharmaceutical Analyst at GlobalData also warned about patient safety: “introducing mRNA carries the risk of activating the immune system.”

article thumbnail

Pulsed field ablation re-energizes the atrial fibrillation market

Clarivate

FDA approval in January 2024. In our September 2023 report on the electrophysiology market, Clarivate projected that by 2028, PFA would represent 50% of the U.S. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. Boston Scientific Corp. s Farapulse.

article thumbnail

Vaxcyte trains its sight on a lucrative market with pneumococcal vaccine

Pharmaceutical Technology

The vaccine demonstrated a similar safety profile to Pfizer’s marketed 20-serotype shot Prevnar 20 at all assessed doses, and showed non-inferior efficacy. In June 2021, the FDA approved Pfizer’s Prevnar 20 for adult use, although a nod for paediatric use is pending. billion and $812 million in 2028. Further plans in the making.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

million by 2028. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021.

Medical 98
article thumbnail

Flow cytometry: advantages in immunotherapy clinical trials

Pharmaceutical Technology

CAGR between 2020 and 2028. FCM data are used to make clinical decisions around safety, efficacy, and pharmacodynamics. The FDA and/or other regulatory agencies typically request validation reports to evaluate the assay performance for the intended purpose.2,3. The importance of validation.